Galera Therapeutics (GRTX) Stock Price, News & Analysis

Company Overview

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

Key Stats

• Today's Range: $0.04 to $0.05
• 50-Day Range: $0.03 to $0.05
• 52-Week Range: $0.02 to $0.29
• Volume: 7,224 shs
• Average Volume: 275,640 shs
• Market Capitalization: $2.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GRTX Stock Analysis - Frequently Asked Questions

How have GRTX shares performed this year?

Galera Therapeutics' stock was trading at $0.0458 at the start of the year. Since then, GRTX stock has decreased by 3.7% and is now trading at $0.0441.
View the best growth stocks for 2025 here.

How were Galera Therapeutics' earnings last quarter?

Galera Therapeutics, Inc. (NASDAQ:GRTX) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by $0.15.

When did Galera Therapeutics IPO?

Galera Therapeutics (GRTX) raised $75 million in an initial public offering (IPO) on Thursday, November 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse acted as the underwriters for the IPO and BTIG was co-manager.

How do I buy shares of Galera Therapeutics?

Shares of GRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Galera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Galera Therapeutics investors own include Energy Transfer (ET), Plug Power (PLUG), NGL Energy Partners (NGL), Universal Display (OLED), NextEra Energy Partners (NEP), Verastem (VSTM) and Alerian MLP ETF (AMLP).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 1/22/2025
• Next Earnings (Estimated): 3/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GRTX
• CUSIP: N/A
• CIK: 1563577
• Web: www.galeratx.com
• Phone: 610-725-1500
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-59,080,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -99.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.74
• Quick Ratio: 9.74

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.41) per share
• Price / Book: -0.02

Miscellaneous

• Outstanding Shares: 54,390,000
• Free Float: 50,639,000
• Market Cap: $2.52 million
• Optionable: Optionable
• Beta: 1.83